Class Action Suit Against NRx Pharmaceuticals Dismissed

RADNOR, Pa., June 22, 2022 /PRNewswire/ — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”), a clinical-stage, biopharmaceutical company, is pleased to announce that on June 13, 2022, the plaintiffs in the securities class action lawsuit captioned “Dal Bosco v. NRx…

Click here to view original post

Be the first to comment

Leave a Reply

Your email address will not be published.


*